Literature DB >> 8095847

Immunohistochemical study of glutathione-related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivity.

J Ogawa1, M Iwazaki, H Inoue, S Koide, A Shohtsu.   

Abstract

BACKGROUND: With resected tumor tissue from 84 patients with lung cancer, the expression of glutathione peroxidase (GPX), glutathione reductase (GR), proliferating cell nuclear antigen (PCNA), and epidermal growth factor receptor (EGFR) was examined in relation to cisdiamminedichloroplatinum (CDDP) sensitivity.
METHODS: The CDDP sensitivity was assessed from an increase of cells in the S-phase or G2M-phase by a DNA histogram after the tumor cells were incubated in a CDDP solution. The expression of GPX, GR, PCNA, and EGFR for each tumor was studied with an indirect immunoperoxidase technique on paraffin-embedded tissues.
RESULTS: The percentage of patients sensitive to CDDP according to the histologic type was 86% for small cell carcinomas, 40% for large cell carcinomas, 31% for squamous cell carcinomas, and 6% for adenocarcinomas. There was an inverse relationship between CDDP sensitivity and the frequency of GPX and GR expression, and both were significantly different among histologic types. The GPX and GR expression was significantly lower in the CDDP-sensitive group than in the resistant group (P < 0.01). However, the expression of PCNA and EGFR was significantly lower in the sensitive group in non-small cell carcinomas and squamous cell carcinomas (P < 0.05).
CONCLUSIONS: From the above findings, an immunohistochemical study of these antigens may be useful for predicting CDDP sensitivity in lung cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095847     DOI: 10.1002/1097-0142(19930401)71:7<2204::aid-cncr2820710707>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.

Authors:  Gillian Bethune; Drew Bethune; Neale Ridgway; Zhaolin Xu
Journal:  J Thorac Dis       Date:  2010-03       Impact factor: 2.895

2.  Influence of sample preparation on cellular glutathione recovery from adherent cells in culture.

Authors:  C Thioudellet; T Oster; P Leroy; A Nicolas; M Wellman
Journal:  Cell Biol Toxicol       Date:  1995-04       Impact factor: 6.691

Review 3.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

4.  Copy number polymorphisms and anticancer pharmacogenomics.

Authors:  Eric R Gamazon; R Stephanie Huang; M Eileen Dolan; Nancy J Cox
Journal:  Genome Biol       Date:  2011-05-25       Impact factor: 13.583

5.  Endogenous antioxidant enzymes and glutathione S-transferase in protection of mesothelioma cells against hydrogen peroxide and epirubicin toxicity.

Authors:  K Kinnula; K Linnainmaa; K O Raivio; V L Kinnula
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

6.  Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.

Authors:  Boyeon Kim; Young Soo Park; Jae Sook Sung; Jong Won Lee; Saet Byeol Lee; Yeul Hong Kim
Journal:  Cancer Med       Date:  2020-12-12       Impact factor: 4.452

7.  Integrative Modeling of Multiomics Data for Predicting Tumor Mutation Burden in Patients with Lung Cancer.

Authors:  Jun Wang; Peng Chen; Mingyang Su; Guocheng Zhong; Shasha Zhang; Deming Gou
Journal:  Biomed Res Int       Date:  2022-01-20       Impact factor: 3.411

8.  Targeted proteomic assays for quantitation of proteins identified by proteogenomic analysis of ovarian cancer.

Authors:  Ehwang Song; Yuqian Gao; Chaochao Wu; Tujin Shi; Song Nie; Thomas L Fillmore; Athena A Schepmoes; Marina A Gritsenko; Wei-Jun Qian; Richard D Smith; Karin D Rodland; Tao Liu
Journal:  Sci Data       Date:  2017-07-19       Impact factor: 6.444

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.